Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anastasios Stathis

Showing results (31-40 of 131) with videos related to

Pageof 14
Sort By:
The British Journal of Radiology|July 8, 2021
Radiomics in cervical and endometrial cancerLucia Manganaro, Gabriele Maria Nicolino, Miriam Dolciami, et al.
European Journal of Haematology|October 18, 2006
Thrombotic thrombocytopenic purpura associated with renal failure after autologous transplantation for multiple myeloma successfully treated with rituximabElisa Gallerani, Erika Lerch, Elena Romagnani, et al.
Hematological Oncology|November 8, 2023
How to integrate CD19 specific chimeric antigen receptor T cells with other CD19 targeting agents in diffuse large B-cell lymphoma?Carmen de Ramon Ortiz, Sisi Wang, Anastasios Stathis, et al.
Tumori|October 3, 2017
Uncommon somatic mutations in metastatic NUT midline carcinomaStefano Cavalieri, Anastasios Stathis, Alessandra Fabbri, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 14, 2017
Cancer-specific geriatric assessment and quality of life: important factors in caring for older patients with aggressive B-cell lymphomaKarin Ribi, Stéphanie Rondeau, Felicitas Hitz, et al.
British Journal of Haematology|April 4, 2018
Trabectedin is a novel chemotherapy agent for diffuse large B cell lymphomaFilippo Spriano, Elaine Y Chung, Nicolo' Panini, et al.
Investigational New Drugs|August 28, 2021
A phase I trial of lurbinectedin in combination with cisplatin in patients with advanced solid tumorsYannis Metaxas, Carmen Kahatt, Vicente Alfaro, et al.
Investigational New Drugs|February 18, 2018
Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I studyAnastasios Stathis, Ian W Flinn, Sumit Madan, et al.
European Journal of Clinical Investigation|December 24, 2018
Correlation between PSA kinetics and PSMA-PET in prostate cancer restaging: A meta-analysisRicardo Pereira Mestre, Giorgio Treglia, Matteo Ferrari, et al.
Bone Reports|August 14, 2024
Are bone targeted agents still useful in times of immunotherapy? The SAKK 80/19 BTA pilot studyMichael Mark, Alfonso Rojas Mora, Thomas Winder, et al.
Pageof 14

Showing results (31-40 of 131) with videos related to

Sort By:
Pageof 14
The British Journal of Radiology|July 8, 2021
Radiomics in cervical and endometrial cancerLucia Manganaro, Gabriele Maria Nicolino, Miriam Dolciami, et al.
European Journal of Haematology|October 18, 2006
Thrombotic thrombocytopenic purpura associated with renal failure after autologous transplantation for multiple myeloma successfully treated with rituximabElisa Gallerani, Erika Lerch, Elena Romagnani, et al.
Hematological Oncology|November 8, 2023
How to integrate CD19 specific chimeric antigen receptor T cells with other CD19 targeting agents in diffuse large B-cell lymphoma?Carmen de Ramon Ortiz, Sisi Wang, Anastasios Stathis, et al.
Tumori|October 3, 2017
Uncommon somatic mutations in metastatic NUT midline carcinomaStefano Cavalieri, Anastasios Stathis, Alessandra Fabbri, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 14, 2017
Cancer-specific geriatric assessment and quality of life: important factors in caring for older patients with aggressive B-cell lymphomaKarin Ribi, Stéphanie Rondeau, Felicitas Hitz, et al.
British Journal of Haematology|April 4, 2018
Trabectedin is a novel chemotherapy agent for diffuse large B cell lymphomaFilippo Spriano, Elaine Y Chung, Nicolo' Panini, et al.
Investigational New Drugs|August 28, 2021
A phase I trial of lurbinectedin in combination with cisplatin in patients with advanced solid tumorsYannis Metaxas, Carmen Kahatt, Vicente Alfaro, et al.
Investigational New Drugs|February 18, 2018
Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I studyAnastasios Stathis, Ian W Flinn, Sumit Madan, et al.
European Journal of Clinical Investigation|December 24, 2018
Correlation between PSA kinetics and PSMA-PET in prostate cancer restaging: A meta-analysisRicardo Pereira Mestre, Giorgio Treglia, Matteo Ferrari, et al.
Bone Reports|August 14, 2024
Are bone targeted agents still useful in times of immunotherapy? The SAKK 80/19 BTA pilot studyMichael Mark, Alfonso Rojas Mora, Thomas Winder, et al.
Pageof 14